CAJ | 학술논문

目的观察并比较多西他赛联合卡培他滨与奥沙利铂联合卡培他滨治疗老年晚期胃癌的近期疗效和不良反应.方法 82例老年晚期胃癌患者随机分为2组:多西他赛组38例,应用多西他赛(75mg/m2,静脉滴注1 h,第1天)联合卡培他滨[2000 mg/(m2·d),分2次口服,第1～14天]治疗,停服1周,第21天重复治疗;奥沙利铂组44例应用奥沙利铂(100 mg/m2,静脉滴注1 h,第1天)联合卡培他滨(剂量同上)治疗;21 d为1个周期,均化疗2个周期以上,2个周期后复查评价疗效.结果 82例均完成随访,多西他赛组有效率为52.63%(20/38),中位无进展生存期(PFS)为6.1个月.奥沙利铂组有效率为54.55%(24/44),PFS为6.3个月.2组有效率(χ2=0.030,P=0.862)和PFS(χ2=1.39,P=0.19)差异均无统计学意义.2组患者主要不良反应为胃肠反应和骨髓抑制;神经毒性也较常见,多为Ⅰ度或Ⅱ度毒性反应,Ⅲ度或Ⅳ度毒性反应少见,主要为恶心呕吐、白细胞和血小板计数降低.2组间各项不良反应发生率差异无统计学意义(P均>0.05),均无化疗相关性死亡.结论多西他赛联合卡培他滨与奥沙利铂联合卡培他滨治疗老年晚期胃癌疗效相当,不良反应均可耐受.
목적 관찰병비교다서타새연합잡배타빈여오사리박연합잡배타빈치료노년만기위암적근기료효화불량반응.방법 82례노년만기위암환자수궤분위2조:다서타새조38례,응용다서타새(75mg/m2,정맥적주1 h,제1천)연합잡배타빈[2000 mg/(m2·d),분2차구복,제1～14천]치료,정복1주,제21천중복치료;오사리박조44례응용오사리박(100 mg/m2,정맥적주1 h,제1천)연합잡배타빈(제량동상)치료;21 d위1개주기,균화료2개주기이상,2개주기후복사평개료효.결과 82례균완성수방,다서타새조유효솔위52.63%(20/38),중위무진전생존기(PFS)위6.1개월.오사리박조유효솔위54.55%(24/44),PFS위6.3개월.2조유효솔(χ2=0.030,P=0.862)화PFS(χ2=1.39,P=0.19)차이균무통계학의의.2조환자주요불량반응위위장반응화골수억제;신경독성야교상견,다위Ⅰ도혹Ⅱ도독성반응,Ⅲ도혹Ⅳ도독성반응소견,주요위악심구토、백세포화혈소판계수강저.2조간각항불량반응발생솔차이무통계학의의(P균>0.05),균무화료상관성사망.결론 다서타새연합잡배타빈여오사리박연합잡배타빈치료노년만기위암료효상당,불량반응균가내수.
Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits.